Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report

World Journal of Gastroenterology

Volumn 16, Issue 43, 2010, Pages 5518-5522

  Wang, Yubao ^a   Speeg, Kermit V ^a   Washburn, William Kenneth ^a   Halff, Glenn ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Mammalian target of rapamycin inhibitor; Sirolimus; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; AMINOTRANSFERASE; CREATINE; RAPAMYCIN; SORAFENIB; TACROLIMUS;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; HAND FOOT SYNDROME; HEPATITIS C; HOSPITALIZATION; HUMAN; HYPERKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG METASTASIS; LUNG NODULE; MALE; SEROLOGY; THORAX PAIN; TREATMENT RESPONSE;

EID: 78649687544     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i43.5518     Document Type: Article

References (18)

1. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epi-demiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 2007; 167: 1983-1989
2. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-1014
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917
4. Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer J 2008; 14: 123-127
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
6. Takada Y, Uemoto S. Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci 2010; 17: 527-532
7. Nocera A, Andorno E, Tagliamacco A, Morelli N, Bottino G, Ravazzoni F, Casaccia M, Barocci S, Alice S, Santori G, Ghirelli R, Valente U. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc 2008; 40: 1950-1952
8. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918
9. Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 2005; 6: 835-846
10. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ. Involvement of PI3K/ PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 2009; 39: 177-186
11. Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, Poon D, Ngo VC, Tran E. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2009; 13: 1371-1380
12. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo KC. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009; 13: 2673-2683
13. Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008; 13: 66-70
14. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of postransplant lung metastases from hepatocel-lular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005; 79: 855-857
15. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-1767
16. Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, Stoupis C, Dufour JF. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of he-patocellular carcinoma. J Hepatol 2007; 46: 840-848
17. Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, PeckRadosavljevic M, Wacheck V. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007; 83: 425-432
18. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is as-sociated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27: 255-261